The above nine hot papers included two meta-analyses, and the results showed that SGLT2 inhibitors were associated with a reduced risk of major adverse CV events and renal outcomes (36), as well as a reduced combined risk of CV death or hospitalization due to HF in patients with or without diabetes (4). The gene discussed is SLC5A2; the disease is diabetes mellitus.